1. Home
  2. SJT vs IPHA Comparison

SJT vs IPHA Comparison

Compare SJT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

SELL

Current Price

$4.37

Market Cap

139.8M

Sector

Energy

ML Signal

SELL

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

SELL

Current Price

$1.51

Market Cap

165.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SJT
IPHA
Founded
1980
1999
Country
United States
France
Employees
495
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.8M
165.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SJT
IPHA
Price
$4.37
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
★ 540.7K
45.2K
Earning Date
11-12-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$1.17
52 Week High
$6.55
$2.71

Technical Indicators

Market Signals
Indicator
SJT
IPHA
Relative Strength Index (RSI) 70.36 33.83
Support Level $4.13 $1.34
Resistance Level $4.66 $1.83
Average True Range (ATR) 0.28 0.10
MACD 0.05 -0.00
Stochastic Oscillator 72.01 5.56

Price Performance

Historical Comparison
SJT
IPHA

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: